Company News from the 10/31/06 News Brief

Share this article:
Hit by generic competition to blood thinner Plavix (clopidogrel) in the US and by measures to curb healthcare costs in France and Germany, Sanofi-Aventis said profits slipped 12% in the third quarter. Sales fell 4.2% to $8.8 billion after the Aug. 8 launch of generic clopidogrel by Canadian generics firm Apotex. The Paris-based firm said reforms in France and Germany put pressure on doctors to curb prescriptions, and some products were harmed by parallel imports. Still, it saw increased sales of inline products Lovenox (stroke), Taxotere and Eloxatin, both for cancer, as well as for Ambien (insomnia) and Lantus (diabetes). Obesity drug Acomplia (rimonabant), which has launched in seven European countries, rang up third-quarter sales of $14 million. The drug is under review by the FDA, and Sanofi-Aventis said it submitted a complete response this month to the agency’s approvable letter, issued in February.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.